GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (FRA:22Z) » Definitions » Sale Of Property, Plant, Equipment

Zealand Pharma AS (FRA:22Z) Sale Of Property, Plant, Equipment : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS Sale Of Property, Plant, Equipment?

Zealand Pharma AS's sale of property, plant, equipment for the three months ended in Dec. 2024 was €0.00 Mil. It means Zealand Pharma AS gained €0.00 Mil from selling property, plant, and equipment. Zealand Pharma AS's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Sep. 2024 ), Zealand Pharma AS gained the same money from selling property, plant, and equipment in Dec. 2024 (€0.00 Mil).

Zealand Pharma AS Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Zealand Pharma AS's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Sale Of Property, Plant, Equipment Chart

Zealand Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zealand Pharma AS Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (FRA:22Z) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:GMAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX SMMT INSM HKSE:02269 BMRN RPRX
Traded in Other Exchanges
ZLDPF:USA ZEALc:UK 0NZU:UK ZEAL:Denmark
Address
Sydmarken 11, Soborg, DNK, DK-2860
Website
https://www.zealandpharma.com
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines